Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Oragenics, Inc. (NYSE American: OGEN) has announced that CEO Kim Murphy will participate in the World Vaccine Congress in Washington, D.C., from April 3-6, 2023. The focus will be on the company's lead COVID-19 intranasal vaccine candidate, NT-CoV2-1, which has shown promising safety and immunogenicity results, paving the way for upcoming Phase 1 clinical trials. Oragenics recently entered a global license agreement with Inspirevax Inc. for a novel adjuvant, BDX301, to enhance NT-CoV2-1. This intranasal vaccine aims to provide advantages over injectable vaccines, including targeting mucosal immunity.
Oragenics, Inc. (NYSE American: OGEN) has reported positive results from third-party lab tests on its lantibiotics platform, targeting antibiotic-resistant infections. The tests showed that strains of Staphylococcus aureus (MRSA) and Enterococci (VRE) remain sensitive to Oragenics' compounds, despite resistance to standard therapies. This collaboration with Linnaeus Bioscience Inc. reinforces the efficacy of lantibiotics in combating serious infections. With over 2.8 million resistant infections annually in the U.S., Oragenics is focused on meeting this need through innovative antibiotic development.
Oragenics, Inc. (NYSE American: OGEN) has appointed Janet Huffman as Chief Financial Officer, effective March 7, 2023. With over 12 years of experience in financial leadership in healthcare, Huffman's expertise in capital raising and M&A will be crucial for Oragenics' development plans. She previously served as CFO of TRxADE HEALTH and was integral in the merger of Banyan Pediatric Care Centers. Huffman aims to enhance stakeholder value through strategic financial management. Oragenics focuses on combating infectious diseases, particularly with its intranasal COVID-19 vaccine candidate, NT-CoV2-1, leveraging research from the NIH.
Oragenics, Inc. (AMEX: OGEN) has entered an exclusive global licensing agreement with Inspirevax Inc. for the development of NT-CoV2-1, its lead intranasal COVID-19 vaccine candidate, utilizing Inspirevax's BDX301 adjuvant. This partnership establishes a Joint Development Committee to oversee collaborative efforts. Oragenics will be responsible for milestone and royalty payments, with potential for future intranasal vaccine developments. The agreement aims to address unmet medical needs. In December 2022, Oragenics reported no toxicity from prior studies, suggesting a favorable safety profile for NT-CoV2-1.
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
